Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06088992 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)

StatusActive, Not Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2024 (before its estimated October 30, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jan 30, 2024 to Oct 30, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 30, 2024 to Oct 30, 2028
    • Site details revised
    v3
  2. Study Status, Eligibilityv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutationsin RPE65 gene.
Trial Details
NCT Number NCT06088992
Lead Sponsor Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators: HuidaGene Therapeutics Co., Ltd.
Conditions
(from sponsor)		 Leber Congenital Amaurosis
Related terms Leber Congenital Amaurosis
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov